Liu Y, Hermanson M, Grandér D, Merup M, Wu X, Heyman M, Rasool O, Juliusson G, Gahrton G, Detlofsson R, Nikiforova N, Buys C, Söderhäll S, Yankovsky N, Zabarovsky E, Einhorn S
Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Blood. 1995 Sep 1;86(5):1911-5.
Previous studies have indicated that a candidate tumor suppressor gene resides telomeric of the RB1 gene at 13q14, a region that is commonly deleted in B-cell chronic lymphocytic leukemia (B-CLL). In this study, we have evaluated the frequency and minimal region of overlap for 13q deletions in malignant cells from various lymphoid neoplasms. We observed losses at 13q14 in 33/75 (44%) B-CLL cases, four of 16 (25%) non-Hodgkin's lymphoma (NHL) cases, eight of 29 (28%) patients with acute lymphocytic leukemia (ALL), and one of 15 T-cell lines. In some ALL cases, inactivation of the RB1 gene is suggested as the important event in the 13q deletions. The most commonly deleted marker in CLL and NHL was D13S319, between RBkpt and the D13S25 loci. Homozygous deletions of this marker were observed in 10 of 75 B-CLL cases, in six of which the homozygous deletions included only the D13S319 locus. Our data suggest that 13q deletions are common in lymphoid neoplasms, and that deletion of a candidate tumor suppressor gene(s) in the vicinity of the D13S319 marker is a tumorigenic event in these diseases.
先前的研究表明，一个候选肿瘤抑制基因位于13q14上RB1基因的端粒区域，该区域在B细胞慢性淋巴细胞白血病（B-CLL）中常发生缺失。在本研究中，我们评估了各种淋巴样肿瘤恶性细胞中13q缺失的频率和最小重叠区域。我们在33/75（44%）的B-CLL病例、16例非霍奇金淋巴瘤（NHL）病例中的4例（25%）、29例急性淋巴细胞白血病（ALL）患者中的8例（28%）以及15个T细胞系中的1个中观察到13q14缺失。在一些ALL病例中，RB1基因失活被认为是13q缺失中的重要事件。CLL和NHL中最常缺失的标记是RBkpt和D13S25位点之间 的D13S319。在75例B-CLL病例中的10例中观察到该标记的纯合缺失，其中6例的纯合缺失仅包括D13S319位点。我们的数据表明，13q缺失在淋巴样肿瘤中很常见，并且D13S319标记附近的一个或多个候选肿瘤抑制基因的缺失是这些疾病中的致瘤事件。
